This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G71.3 | Special Copayment Reduction: V012 | Coverage period: 5 years |
| Main Korean name | Mitochondrial myopathy, not elsewhere classified (MELAS syndrome) |
| B. Synonyms | Mitochondrial myopathy, not elsewhere classified, MELAS syndrome, Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes |
| C. Adult onset | Possible first presentation in adulthood — age at onset varies from childhood to the 40s; mean onset around 15 years, but many cases of first onset in adulthood reported |
| 1. History | → Go to section | First named by Pavlakis and Rowland in 1984 |
| 2. Causes | → Go to section | mtDNA 3243A>G (MT-TL1, ~80%), oxidative phosphorylation defect |
| 3. Genetics | → Go to section | Maternal inheritance; the concept of heteroplasmy is key |
| 4. Epidemiology | → Go to section | Prevalence about 1–10/100,000; 3243A>G carriers about 1/400 |
| 5. Pathophysiology | → Go to section | tRNA Leu dysfunction → oxidative phosphorylation defect → lactate accumulation → damage to energy-dependent tissues |
| 6. Symptoms | → Go to section | Tetrad of stroke-like episodes, epilepsy, myopathy and lactic acidosis |
| 7. Signs | → Go to section | Short-term memory impairment, visual field defects, ptosis, hemiparesis, hearing loss |
| 8. Screening | → Go to section | Plasma and CSF lactate, serum CK, diffusion-weighted brain MRI |
| 9. Diagnosis | → Go to section | Detection of mtDNA variants (blood, urine, muscle), muscle biopsy (RRF) |
| 10. Treatment | → Go to section | Coenzyme Q10, riboflavin, L-arginine; IV arginine during episodes |
| 11. Prognosis | → Go to section | Gradual cognitive decline with repeated stroke-like episodes |
| 12. Prevention | → Go to section | Genetic counseling; assisted reproductive technology (mitochondrial replacement therapy under study) |
| 13. References | → Go to section | 10 key references |
MELAS syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes) was first named in 1984 by Pavlakis, Phillips, DiMauro, De Vivo, Rowland and colleagues, who described a group of patients with the characteristic triad of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes. This name provided a conceptual framework that unified clinical cases previously reported under various names.
In 1988, Wallace et al. showed that a point mutation in mitochondrial DNA (mtDNA) was the cause of Leber hereditary optic neuropathy (LHON), establishing that mtDNA variants can cause human disease. In 1990, Goto et al. and Shoffner et al. each independently first reported that an A-to-G substitution at nucleotide 3243 of mtDNA (m.3243A>G, MT-TL1 gene) is observed in about 80% of patients with MELAS. This mutation is located in the gene encoding mitochondrial leucine tRNA (tRNA^Leu(UUR)).
Through the 1990s, the unique concepts of mitochondrial genetics — heteroplasmy, the bottleneck, the threshold effect and maternal inheritance — were established. Since the 2000s, MELAS has been re-recognized as a complex multisystem disease that goes beyond the simple triad to include diverse systemic manifestations such as diabetes, hearing loss, cardiomyopathy and psychiatric abnormalities, and biomarker research for early diagnosis and clinical treatment trials are actively under way.
MELAS is mainly caused by point mutations in mitochondrial DNA (mtDNA), and the m.3243A>G mutation (MT-TL1 gene, mitochondrial tRNA Leu(UUR)) is identified in about 80% of all patients with MELAS. In the remaining 20%, other variants within MT-TL1 such as m.3271T>C and m.3252A>G, and variants in the MT-ND5 (NADH dehydrogenase subunit 5), MT-ND1, MT-TH and MT-TV genes, have been reported as causes.
m.3243A>G is located in the dihydrouridine (DHU) stem of tRNA^Leu(UUR), and this variant inhibits the normal post-transcriptional modification of the tRNA, particularly the formation of taurine-modified uridine (τm5U). Loss of this modification causes translation errors at UUR codons (encoding Leu) and reduces the translation efficiency of mitochondrially encoded proteins essential for the function of OXPHOS complexes I and IV in particular.
As a result, reduced function of mitochondrial oxidative phosphorylation (OXPHOS) complexes I, III and IV → electron transport chain abnormality → reduced ATP production + excessive generation of reactive oxygen species (ROS) → damage to energy-dependent tissues (brain, muscle, heart, kidney). In the brain, energy deficiency of the neurovascular unit acts as the direct mechanism of stroke-like episodes.
MELAS follows a maternal inheritance pattern. Mitochondria are cytoplasmic organelles, and because sperm mitochondria are excluded at fertilization, mtDNA is transmitted to children only from the mother. Therefore, if the mother carries variant mtDNA it can be transmitted to both sons and daughters, but fathers do not transmit it to their children.
The key concept of heteroplasmy refers to the coexistence of normal and variant mtDNA within a cell. The heteroplasmy level varies between tissues, between individuals and over time. The heteroplasmy level in blood may differ from that in muscle, urinary sediment and buccal mucosal cells, and it is generally higher in urine or muscle than in blood. The threshold effect means that reduced OXPHOS function manifests as clinical symptoms when the proportion of variant mtDNA in a tissue exceeds a certain level (generally 60–80% or more).
m.3243A>G carriers show a very wide clinical spectrum, from asymptomatic to classic MELAS, and phenotypic variation is large even within the same family. In genetic counseling, it should be explained that even if the heteroplasmy level is low, it may become higher in children (genetic bottleneck).
| Mutation | Gene | MELAS proportion | Other phenotypes |
|---|---|---|---|
| m.3243A>G | MT-TL1 | ~80% | Diabetes + hearing loss (MIDD), CPEO, Leigh syndrome |
| m.3271T>C | MT-TL1 | ~5% | Classic MELAS |
| m.13513G>A | MT-ND5 | ~5% | MELAS/Leigh overlap |
| Other | Variable | ~10% | Various mitochondrial phenotypes |
The prevalence of MELAS syndrome is estimated at about 1–10/100,000. Carriers of the m.3243A>G mutation are estimated at about 1/400–1/500 in the general population, and only a minority of them actually show the classic MELAS phenotype. Considering the broad clinical spectrum (including mild forms such as diabetes and hearing loss), the prevalence of all m.3243A>G-related disease is much higher.
Age at onset varies from childhood (usually 2–10 years) to adulthood (40s), with a mean age at onset of about 10–15 years. However, cases of first onset in adulthood are not uncommon, so MELAS should always be considered when differentiating stroke in adult neurology outpatient clinics. There is no clear sex difference, and because inheritance is maternal, family history-taking must determine whether maternal relatives have diabetes, hearing loss, migraine or early death.
In Korea, too, it is eligible for rare disease Special Copayment Reduction, and cases confirmed as MELAS in endocrinology and otolaryngology in the form of diabetes + hearing loss are increasing.
The pathophysiology of MELAS is understood as a combination of energy metabolism failure and vascular endothelial dysfunction.
The m.3243A>G variant interferes with 5-taurinomethyluridine (τm⁵U) modification, one of the post-transcriptional modifications of tRNA^Leu(UUR). This reduces the translation efficiency of UUR codons and decreases synthesis of the mitochondrially encoded subunits of complex I (NADH dehydrogenase) and complex IV (cytochrome c oxidase). Reduced electron transport chain efficiency → reduced ATP production, excess reactive oxygen species (ROS), increased NADH/NAD⁺ ratio → increased conversion of pyruvate to lactate → lactic acidosis.
Unlike conventional thromboembolic stroke, stroke-like episodes (SLE) show a mix of lesion distribution that crosses vascular territories and a pattern of cytotoxic edema on diffusion-weighted MRI. The main mechanisms proposed, acting in combination, are: (1) energy deficiency of cerebral vascular endothelial cells and smooth muscle cells → abnormal vascular regulation; (2) direct energy depletion of the neurovascular unit; (3) vasoconstriction due to reduced NO (nitric oxide) synthesis → tissue ischemia; (4) excitotoxicity due to excessive glutamate release.
The classic tetrad of MELAS is as follows.
⚠ Metformin contraindicated: in patients with MELAS-related diabetes, metformin is contraindicated because it markedly increases the risk of lactic acidosis. It is replaced with insulin or a sulfonylurea.
Clinical caution: with a combination of stroke-like symptoms before age 40 + elevated lactate + maternal family history (diabetes, hearing loss, headache), MELAS must be differentiated. Atypical lesions extending beyond vascular territories on diffusion-weighted brain MRI are characteristic.
| Test | Findings and significance |
|---|---|
| Plasma lactate/pyruvate | Elevated lactate at rest (≥2 mmol/L criterion; more marked after exercise). A lactate:pyruvate ratio >20 suggests mitochondrial dysfunction. |
| CSF lactate | Often higher than in plasma. Markedly elevated during SLE episodes. |
| Serum CK | Moderately elevated when myopathy is present. Markedly elevated during episodes of rhabdomyolysis. |
| Brain MRI (DWI + ADC) | During SLE, cortical to subcortical DWI hyperintensity with mixed ADC (mixture of cytotoxic + vasogenic edema). Occipital and parietal involvement common. Does not match vascular distribution. |
| Brain MRS | A lactate doublet peak (1.33 ppm) within lesions is characteristic. |
| Hearing tests | Pure-tone audiometry (PTA); high-frequency sensorineural hearing loss. |
| ECG · echocardiography | WPW pattern, myocardial hypertrophy, dilated cardiomyopathy. |
| Blood glucose and HbA1c | Assessment for diabetes or impaired glucose tolerance. |
Ragged red fibers (RRF) observed on modified Gomori trichrome staining — reflecting accumulation of abnormal mitochondria. Increased COX (cytochrome c oxidase)-negative fibers. Mitochondrial dysmorphism (including paracrystalline inclusions) on electron microscopy.
Hirano and Pavlakis diagnostic criteria: (1) stroke-like episodes, (2) epilepsy or dementia, (3) myopathy or exercise intolerance + one or more of lactic acidosis or RRF. When clinical confirmation is difficult, the mtDNA variant provides the final basis for confirmation.
There is currently no curative treatment for MELAS, and multidisciplinary treatment aimed at symptoms and supplementation of energy metabolism is standard.
MELAS causes progressive neurologic decline through repeated stroke-like episodes and the resulting accumulation of brain damage. Mean survival is about 16–17 years after diagnosis, but individual variation is large. The main causes of death are respiratory failure, heart failure, severe epilepsy, malnutrition and others.
The higher the heteroplasmy level in blood and the more frequent the SLE, the poorer the prognosis. In contrast, early diagnosis, early acute administration of L-arginine, avoidance of episode triggers (fever, infection, dehydration) and regular multidisciplinary monitoring help improve prognosis. Cognitive decline correlates directly with accumulated SLE, and some patients progress to dementia. Hearing loss and diabetes develop relatively early and greatly affect quality of life.
Because mtDNA variants are maternally inherited, application of conventional genetic prevention methods is limited.